13 research outputs found
How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural Enhancement
Correction; Early Access: DOI: 10.1007/s43441-020-00152-0 Early Access: APR 2020Background Pediatric regulations enacted in both Europe and the USA have disrupted the pharmaceutical industry, challenging business and drug development processes, and organizational structures. Over the last decade, with science and innovation evolving, industry has moved from a reactive to a proactive mode, investing in building appropriate structures and capabilities as part of their business strategy to better tackle the challenges and opportunities of pediatric drug development. Methods The EFGCP Children's Medicines Working Party and the IQ Pediatric working group have joined their efforts to survey their member company representatives to understand how pharmaceutical companies are organized to fulfill their regulatory obligations and optimize their pediatric drug development programs. Results Key success factors and recommendations for a fit-for-purpose Pediatric Expert Group (PEG) were identified. Conclusion Pediatric structures and expert groups were shown to be important to support optimization of the development of pediatric medicines.Peer reviewe
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids
Objective. Long-term glucocorticoid use is accompanied by rapid bone loss; however, early treatment with bisphosphonates prevents bone loss and reduces fracture risk. The aim of this study was to examine the effects of two bisphosphonates, i.v. zoledronic acid (ZOL) versus oral risedronate (RIS), on bone turnover markers (BTMs) in subjects with glucocorticoid-induced osteoporosis (GIO). Methods. Patients were randomly stratified according to the duration of pre-study glucocorticoid therapy [prevention subpopulation (ZOL, n = 144; RIS, n = 144) β€3 months, treatment subpopulation (ZOL, n = 272; RIS, n = 273) >3 months]. Changes in Ξ²-C-terminal telopeptides of type 1 collagen (Ξ²-CTx), N-terminal telopeptide of type I collagen (NTx), procollagen type 1 N-terminal propeptide (P1NP) and bone-specific alkaline phosphatase (BSAP) from baseline were measured on day 10 and months 3, 6 and 12. Results. At most time points, there were significantly greater reductions (P < 0.05) in the concentrations of serum Ξ²-CTx, P1NP and BSAP and urine NTx in subjects on ZOL compared with RIS in both males and females of the treatment and prevention subpopulations. In pre- and post-menopausal women, there were significantly greater reductions in the concentrations of BTMs with ZOL compared with RIS. At 12 months, ZOL had significantly greater reductions compared with RIS (P < 0.05) for Ξ²-CTx, P1NP, BSAP and NTx levels, independent of glucocorticoid dose. Conclusions. Once-yearly i.v. infusion of ZOL 5 mg was well tolerated in different subgroups of GIO patients. ZOL was non-inferior to RIS and even superior to RIS in the response of BTMs in GIO patients. Trial registration: ClinicalTrials.gov, http://clinicaltrials.gov, NCT0010062
The Effect of 3 Versus 6 Years of Zoledronic Acid Treatment of Osteoporosis: A Randomized Extension to the HORIZON-Pivotal Fracture Trial (PFT)
ABSTRACT Zoledronic acid 5 mg (ZOL) annually for 3 years reduces fracture risk in postmenopausal women with osteoporosis. To investigate longterm effects of ZOL on bone mineral density (BMD) and fracture risk, the Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial (HORIZON-PFT) was extended to 6 years. In this international, multicenter, double-blind, placebocontrolled extension trial, 1233 postmenopausal women who received ZOL for 3 years in the core study were randomized to 3 additional years of ZOL (Z6, n ΒΌ 616) or placebo (Z3P3, n ΒΌ 617). The primary endpoint was femoral neck (FN) BMD percentage change from year 3 to 6 in the intent-to-treat (ITT) population. Secondary endpoints included other BMD sites, fractures, biochemical bone turnover markers, and safety. In years 3 to 6, FN-BMD remained constant in Z6 and dropped slightly in Z3P3 (between-treatment difference ΒΌ 1.04%; 95% confidence interval 0.4 to 1.7; p ΒΌ 0.0009) but remained above pretreatment levels. Other BMD sites showed similar differences. Biochemical markers remained constant in Z6 but rose slightly in Z3P3, remaining well below pretreatment levels in both. New morphometric vertebral fractures were lower in the Z6 (n ΒΌ 14) versus Z3P3 (n ΒΌ 30) group (odds ratio ΒΌ 0.51; p ΒΌ 0.035), whereas other fractures were not different. Significantly more Z6 patients had a transient increase in serum creatinine >0.5 mg/dL (0.65% versus 2.94% in Z3P3). Nonsignificant increases in Z6 of atrial fibrillation serious adverse events (2.0% versus 1.1% in Z3P3; p ΒΌ 0.26) and stroke (3.1% versus 1.5% in Z3P3; p ΒΌ 0.06) were seen. Postdose symptoms were similar in both groups. Reports of hypertension were significantly lower in Z6 versus Z3P3 (7.8% versus 15.1%, p < 0.001). Small differences in bone density and markers in those who continued versus those who stopped treatment suggest residual effects, and therefore, after 3 years of annual ZOL, many patients may discontinue therapy up to 3 years. However, vertebral fracture reductions suggest that those at high fracture risk, particularly vertebral fracture, may benefit by continued treatment. (ClinicalTrials.gov identifier: NCT00145327).
ZOLEDRONOVAYa KISLOTA V PROFILAKTIKE POTERI KOSTNOY TKANI U zhENShchIN POSTMENOPAUZAL'NOGO VOZRASTA S OSTEOPENIEY
ΠΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠ° ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ², ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎ Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ ΠΊΠΎΡΡΠΈ ΠΈ ΠΏΠΎΠ·Π²ΠΎΠ½ΠΊΠΎΠ², - ΡΡΠΎ Π²Π°ΠΆΠ½Π°Ρ ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π·Π΄ΡΠ°Π²ΠΎΠΎΡ
ΡΠ°Π½Π΅Π½ΠΈΡ. ΠΠΎΠ΄ΠΎΠ±Π½ΡΠ΅ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΡ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΠΏΠΎΠ²ΡΡΠ΅Π½Π½ΡΠΌ ΡΠΈΡΠΊΠΎΠΌ ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΠΈ ΡΠΌΠ΅ΡΡΠΈ, ΠΏΠΎΡΡΠΎΠΌΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½Π°Ρ ΡΡΡΠ°ΡΠ΅Π³ΠΈΡ ΠΈΡ
ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΌΠΎΠΆΠ΅Ρ ΠΎΠΊΠ°Π·Π°ΡΡ Π·Π½Π°ΡΠΈΡΠ΅Π»ΡΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π΅ΠΌΠΎΡΡΡ ΠΈ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΎ ΠΌΠ΅Π½ΡΡΠ΅Π΅, Π½ΠΎ ΡΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΌΠ΅ΡΡΠ½ΠΎΡΡΡ ΠΏΠΎΠΆΠΈΠ»ΡΡ
Π»ΡΠ΄Π΅ΠΉ. 1-3 Π₯ΠΎΡΡ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΎΡΡΠ΅ΠΏΠ΅Π½ΠΈΠ΅ΠΉ ΡΠΈΡΠΊ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² Π½ΠΈΠΆΠ΅, ΡΠ΅ΠΌ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ ΡΠΎΠ³ΠΎ ΠΆΠ΅ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·ΠΎΠΌ, ΡΠ΅ΠΌ Π½Π΅ ΠΌΠ΅Π½Π΅Π΅, ΠΏΡΠΈ ΠΎΡΡΡΡΡΡΠ²ΠΈΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ Ρ Π½ΠΈΡ
Π²ΡΡΠΎΠΊΠ° Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°. ΠΠΎΠ»Π΅Π΅ ΡΠΎΠ³ΠΎ, Π±ΠΎΠ»ΡΡΠΈΠ½ΡΡΠ²ΠΎ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΡΠ΅Π³ΠΈΡΡΡΠΈΡΡΡΡ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ Ρ ΠΎΡΡΠ΅ΠΎΠΏΠ΅Π½ΠΈΠ΅ΠΉ. 4 Π ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ
ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΡΡ
ΠΆΠ΅Π½ΡΠΈΠ½Π°ΠΌ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ ΠΎΡΡΠ΅ΠΎΠΏΠ΅Π½ΠΈΠ΅ΠΉ ΠΈ ΡΠΎ ΡΡΠ΅Π΄Π½ΠΈΠΌ ΠΈΠ»ΠΈ Π²ΡΡΠΎΠΊΠΈΠΌ ΡΠΈΡΠΊΠΎΠΌ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² (ΠΎΡΠ΅Π½ΠΈΠ²Π°ΡΡ Ρ ΠΏΠΎΠΌΠΎΡΡΡ Π²Π°Π»ΠΈΠ΄ΠΈΡΠΎΠ²Π°Π½Π½ΡΡ
ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ², ΡΠ°ΠΊΠΈΡ
ΠΊΠ°ΠΊ FRAX) ΠΏΡΠ΅Π΄Π»Π°Π³Π°Π΅ΡΡΡ Π½Π°Π·Π½Π°ΡΠ°ΡΡ Π»Π΅ΠΊΠ°ΡΡΡΠ²Π΅Π½Π½ΡΠ΅ ΡΡΠ΅Π΄ΡΡΠ²Π°, ΠΏΡΠ΅Π΄Π½Π°Π·Π½Π°ΡΠ΅Π½Π½ΡΠ΅ Π΄Π»Ρ Π»Π΅ΡΠ΅Π½ΠΈΡ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·Π°. 5 ΠΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΡΠ΅ Π±ΠΈΡΡΠΎΡΡΠΎΠ½Π°ΡΡ ΠΏΡΠ΅Π΄ΡΠΏΡΠ΅ΠΆΠ΄Π°ΡΡ ΠΏΠΎΡΠ΅ΡΡ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ ΠΏΠΎΡΠ»Π΅ Π½Π°ΡΡΡΠΏΠ»Π΅Π½ΠΈΡ ΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Ρ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Π±ΠΎΠ»Π΅Π΅ ΠΌΠΎΠ»ΠΎΠ΄ΠΎΠ³ΠΎ ΠΈ ΡΡΠ°ΡΡΠ΅Π³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° 6-8 ΠΠ΄Π½Π°ΠΊΠΎ Π² ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅ ΠΌΠ½ΠΎΠ³ΠΈΠ΅ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΊΠΈ ΠΏΠ»ΠΎΡ
ΠΎ Π²ΡΠΏΠΎΠ»Π½ΡΡΡ ΡΠ΅ΠΊΠΎΠΌΠ΅Π½Π΄Π°ΡΠΈΠΈ Π²ΡΠ°ΡΠ° ΠΈ ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΡ ΠΏΠ΅ΡΠΎΡΠ°Π»ΡΠ½ΡΠ΅ Π±ΠΈΡΡΠΎΡΡΠΎΠ½Π°ΡΡ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ Π½Π΅ Π±ΠΎΠ»Π΅Π΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ
ΠΌΠ΅ΡΡΡΠ΅Π². 9 Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π²Π°ΠΆΠ½ΠΎΠ΅ Π·Π½Π°ΡΠ΅Π½ΠΈΠ΅ ΠΈΠΌΠ΅Π΅Ρ ΠΏΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠ΅Π³ΠΎ Π²ΡΡΠΎΠΊΡΡ ΠΏΡΠΈΠ²Π΅ΡΠΆΠ΅Π½Π½ΠΎΡΡΡ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠΊ. Π ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡΡ
Π΄ΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ Π΅ΠΆΠ΅Π³ΠΎΠ΄Π½ΡΠ΅ ΠΈΠ½ΡΡΠ·ΠΈΠΈ Π·ΠΎΠ»Π΅Π΄ΡΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ Π² Π΄ΠΎΠ·Π΅ 5 ΠΌΠ³ Π² ΡΠ΅ΡΠ΅Π½ΠΈΠ΅ 3 Π»Π΅Ρ ΡΠ½ΠΈΠΆΠ°ΡΡ ΡΠΈΡΠΊ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΠΏΠΎΠ·Π²ΠΎΠ½ΠΊΠΎΠ², Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ ΠΊΠΎΡΡΠΈ ΠΈ Π²Π½Π΅ΠΏΠΎΠ·Π²ΠΎΠ½ΠΎΡΠ½ΡΡ
ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² ΠΈ ΡΠ²Π΅Π»ΠΈΡΠΈΠ²Π°ΡΡ ΠΠΠ ΠΏΠΎΡΡΠ½ΠΈΡΠ½ΡΡ
ΠΏΠΎΠ·Π²ΠΎΠ½ΠΊΠΎΠ² ΠΈ Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ ΠΊΠΎΡΡΠΈ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ Ρ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΡΠΌ ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΠ·ΠΎΠΌ. 10 ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, ΠΏΡΠ΅ΠΏΠ°ΡΠ°Ρ ΡΠ½ΠΈΠΆΠ°Π» ΡΠΈΡΠΊ ΠΏΠΎΠ²ΡΠΎΡΠ½ΡΡ
ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ ΡΠ²Π½ΡΡ
ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌΠΎΠ² Ρ ΠΌΡΠΆΡΠΈΠ½ ΠΈ ΠΆΠ΅Π½ΡΠΈΠ½, Π½Π΅Π΄Π°Π²Π½ΠΎ ΠΏΠ΅ΡΠ΅Π½Π΅ΡΡΠΈΡ
ΠΎΡΡΠ΅ΠΎΠΏΠΎΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΠ΅ΡΠ΅Π»ΠΎΠΌ Π±Π΅Π΄ΡΠ΅Π½Π½ΠΎΠΉ ΠΊΠΎΡΡΠΈ. 11 Π¦Π΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΎ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡΠΈΠΌΠΎΡΡΠΈ Π²Π½ΡΡΡΠΈΠ²Π΅Π½Π½ΡΡ
ΠΈΠ½ΡΡΠ·ΠΈΠΉ Π·ΠΎΠ»Π΅Π΄ΡΠΎΠ½ΠΎΠ²ΠΎΠΉ ΠΊΠΈΡΠ»ΠΎΡΡ Π² Π΄ΠΎΠ·Π΅ 5 ΠΌΠ³ Ρ ΠΆΠ΅Π½ΡΠΈΠ½ ΠΏΠΎΡΡΠΌΠ΅Π½ΠΎΠΏΠ°ΡΠ·Π°Π»ΡΠ½ΠΎΠ³ΠΎ Π²ΠΎΠ·ΡΠ°ΡΡΠ° Ρ ΠΎΡΡΠ΅ΠΎΠΏΠ΅Π½ΠΈΠ΅ΠΉ. Π 2-Π»Π΅ΡΠ½Π΅ΠΌ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΠΈΠ·ΡΡΠ°Π»ΠΈ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ Π΄Π²ΡΡ
ΠΈ ΠΎΠ΄Π½ΠΎΠΉ ΠΈΠ½ΡΡΠ·ΠΈΠΈ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠ°, ΡΡΠΎΠ±Ρ ΠΎΡΠ΅Π½ΠΈΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΡ ΡΠΈΡΠ»Π° ΠΈΠ½ΡΡΠ·ΠΈΠΉ Π΄Π»Ρ ΠΏΡΠΎΡΠΈΠ»Π°ΠΊΡΠΈΠΊΠΈ ΠΏΠΎΡΠ΅ΡΠΈ ΠΊΠΎΡΡΠ½ΠΎΠΉ ΡΠΊΠ°Π½ΠΈ
Inclusion of Pregnant and Breastfeeding Women in Research β Efforts and Initiatives
Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethicoβlegal challenges that have remained entrenched in the postβdiethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and βdynamic understanding of medication use in pregnancy
Regulatory strategies for rare diseases under current global regulatory statutes: a discussion with stakeholders
Abstract Rare or orphan diseases often are inherited and overwhelmingly affect children. Many of these diseases have no treatments, are incurable, and have a devastating impact on patients and their families. Regulatory standards for drug approval for rare diseases must ensure that patients receive safe and efficacious treatments. However, regulatory bodies have shown flexibility in applying these standards to drug development in rare diseases, given the unique challenges that hinder efficient and effective traditional clinical trials, including low patient numbers, limited understanding of disease pathology and progression, variability in disease presentation, and a lack of established endpoints. To take steps toward improving rare disease clinical development strategies under current global regulatory statutes, Amicus Therapeutics, Inc. and BioNJ convened a 1-day meeting that included representatives from the Food and Drug Administration (FDA), biopharmaceutical industry, and not-for-profit agencies. The meeting focused on orphan diseases in pediatric and adult patients and was intended to identify potential strategies to overcome regulatory hurdles through open collaboration. During this meeting, several strategies were identified to minimize the limitations associated with low patient numbers in rare diseases, including the use of natural history to generate historical control data in comparisons, simulations, and identifying inclusion/exclusion criteria and appropriate endpoints. Novel approaches to clinical trial design were discussed to minimize patient exposure to placebo and to reduce the numbers of patients and clinical trials needed for providing substantial evidence. Novel statistical analysis approaches were also discussed to address the inherent challenges of small patient numbers. Areas of urgent unmet need were identified, including the need to develop registries that protect patient identities, to establish close collaboration and communication between the sponsor and regulatory bodies to address methodological and statistical challenges, to collaborate in pre-competitive opportunities within multiple sponsors and in conjunction with academia and disease-specific patient advocacy groups for optimal data sharing, and to develop harmonized guidelines for data extrapolation from source to target pediatric populations. Ultimately, these innovations will help in solving many regulatory challenges in rare disease drug development and encourage the availability of new treatments for patients with rare diseases
sj-pdf-1-ctj-10.1177_17407745221132302 β Supplemental material for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance
Supplemental material, sj-pdf-1-ctj-10.1177_17407745221132302 for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance by Christina Bucci-Rechtweg, Angeliki Siapkara, Kristina An Haack Bonnet, Solange Corriol Rohou, Elin Haf Davies, Martine Dehlinger Kremer, Margaret Gamalo, Carmen Moreno, Robert M Nelson and Rhian Thomas Turner in Clinical Trials</p
sj-pdf-2-ctj-10.1177_17407745221132302 β Supplemental material for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance
Supplemental material, sj-pdf-2-ctj-10.1177_17407745221132302 for Strategies to facilitate adolescent access to medicines: Improving regulatory guidance by Christina Bucci-Rechtweg, Angeliki Siapkara, Kristina An Haack Bonnet, Solange Corriol Rohou, Elin Haf Davies, Martine Dehlinger Kremer, Margaret Gamalo, Carmen Moreno, Robert M Nelson and Rhian Thomas Turner in Clinical Trials</p